CD274 and neoplasm: To date, the phase III Keynote 024 and Keynote 042 trials reported that pembrolizumab significantly improves the progression-free survival (PFS) and OS over standard first-line platinum-based chemotherapy; these trials comprise patients with at least 50% PD-L1 and 1% PD-L1 expression in their tumor cells, respectively (Lopes et al. 2018; Reck et al. 2016).